A new series of pyridazinone derivatives as cholinesterases inhibitors: Synthesis, in vitro activity and molecular modeling studies

ArticleAçık Erişim

Özet

Background: The pyridazinone nucleus has been incorporated into a wide variety of therapeutically interesting molecules to transform them into better drugs. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are known to be serine hydrolase enzymes responsible for the hydrolysis of acetylcholine (ACh). Inhibition of cholinesterases is an effective method to curb Alzheimer's disease. Here, we prepared 12 new 6-substituted-3(2H)-pyridazinone-2-acetyl-2-(nonsubstituted/4-substituted benzenesulfonohydrazide) derivatives and evaluated their inhibitory effects on AChE/BChE in pursuit of potent dual inhibitors for Alzheirmer's Disease. We also tried to get insights into binding interactions of the synthesized compounds in the active site of both enzymes by using molecular docking approach. Method: We obtained our compounds by the reaction of various substituted/nonsubstituted benzenesulfonic acid derivatives with 6-substitutedphenyl-3(2H)-pyridazinone-2-yl acetohydrazide and determined their anticholinesterase activities according to the Ellman's method. Molecular docking studies were done using Glide and the results were evaluated on Maestro (Schrödinger, LLC, New York, NY, 2019). Results: The title compounds showed moderate inhibition at 100 μg/ml against both enzymes, yet with better activity against BChE. Compound VI2a emerged as a dual inhibitor with 25.02% and 51.70% inhibition against AChE and BChE, respectively. Conclusion: This study supports that novel pyridazinone derivates may be used for the development of new BChE inhibitory agents. It was less potent than the reference drugs, yet promising for further modifications as a lead. The ability of the compounds to adopt energetically more favourable conformations and to engage in more key interactions in the ECBChE active gorge explains their better activity profile against ECBChE. © 2019 Institute of Pharmacology, Polish Academy of Sciences

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13853Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorÖzçelik, Azime Berna
dc.contributor.authorÖzdemir, Zeynep
dc.contributor.authorSari, Suat
dc.contributor.authorUtku, Semra
dc.contributor.authorUysal, Mehtap
dc.date.accessioned2026-10-18T20:28:39.367388247Z
dc.date.available2026-10-18T20:28:39.367388247Z
dc.date.issued2019
dc.description.abstractBackground: The pyridazinone nucleus has been incorporated into a wide variety of therapeutically interesting molecules to transform them into better drugs. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are known to be serine hydrolase enzymes responsible for the hydrolysis of acetylcholine (ACh). Inhibition of cholinesterases is an effective method to curb Alzheimer's disease. Here, we prepared 12 new 6-substituted-3(2H)-pyridazinone-2-acetyl-2-(nonsubstituted/4-substituted benzenesulfonohydrazide) derivatives and evaluated their inhibitory effects on AChE/BChE in pursuit of potent dual inhibitors for Alzheirmer's Disease. We also tried to get insights into binding interactions of the synthesized compounds in the active site of both enzymes by using molecular docking approach. Method: We obtained our compounds by the reaction of various substituted/nonsubstituted benzenesulfonic acid derivatives with 6-substitutedphenyl-3(2H)-pyridazinone-2-yl acetohydrazide and determined their anticholinesterase activities according to the Ellman's method. Molecular docking studies were done using Glide and the results were evaluated on Maestro (Schrödinger, LLC, New York, NY, 2019). Results: The title compounds showed moderate inhibition at 100 μg/ml against both enzymes, yet with better activity against BChE. Compound VI2a emerged as a dual inhibitor with 25.02% and 51.70% inhibition against AChE and BChE, respectively. Conclusion: This study supports that novel pyridazinone derivates may be used for the development of new BChE inhibitory agents. It was less potent than the reference drugs, yet promising for further modifications as a lead. The ability of the compounds to adopt energetically more favourable conformations and to engage in more key interactions in the ECBChE active gorge explains their better activity profile against ECBChE. © 2019 Institute of Pharmacology, Polish Academy of Sciences
dc.identifier.doi10.1016/j.pharep.2019.07.006
dc.identifier.eissn2299-5684
dc.identifier.endpage1263
dc.identifier.issn2299-5684
dc.identifier.issue6
dc.identifier.pmid31675671
dc.identifier.scopus2-s2.0-85074141768
dc.identifier.startpage1253
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13853
dc.identifier.volume71
dc.identifier.wosWOS:000502249300038
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofPharmacological Reports
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject3(2H)-Pyridazinone
dc.subjectAChE inhibitor
dc.subjectBChE inhibitor
dc.subjectHydrazone
dc.subjectMolecular modelling
dc.subjectAcetylcholinesterase
dc.subjectAlzheimer Disease
dc.subjectButyrylcholinesterase
dc.subjectCholinesterase Inhibitors
dc.subjectHumans
dc.subjectMolecular Docking Simulation
dc.subjectStructure-Activity Relationship
dc.subject2 (3 (4 chlorophenyl) 6 oxopyridazin 1(6 h) yl) n' (phenylsulfonyl)acetohydrazide
dc.subjectacetic acid derivative
dc.subjectbenzenesulfonic acid derivative
dc.subjectcholinesterase
dc.subjectcholinesterase inhibitor
dc.subjectdonepezil
dc.subjectgalantamine
dc.subjectphysostigmine
dc.subjectpyridazinone derivative
dc.subjectrivastigmine
dc.subjecttacrine
dc.subjectunclassified drug
dc.subjectArticle
dc.subjectcholinesterase inhibition
dc.subjectcontrolled study
dc.subjectdrug conformation
dc.subjectdrug potency
dc.subjectdrug protein binding
dc.titleA new series of pyridazinone derivatives as cholinesterases inhibitors: Synthesis, in vitro activity and molecular modeling studies
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus30
rdl.citation.wos20
rdl.departmentGazi University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Ankara, Turkey
rdl.departmentErzincan Binali Yıldırım University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)